Loading
A phase 3 trial testing Ipatasertib, now recruiting.
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study is a phase 3 interventional study registered as NCT05862285, led by Hoffmann-La Roche, and recruiting on the registry. Official title: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study. Planned enrolment is 100 participants (estimated). The study started in 2023-06-01 and primary completion is expected in 2033-03-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipatasertib, Roche / Genentech.
Shares Ipatasertib, Roche / Genentech.
Shares Ipatasertib, Roche / Genentech.
Shares Ipatasertib, Roche / Genentech.
Shares Ipatasertib, Roche / Genentech.
Shares Ipatasertib, Roche / Genentech.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/